Belantamab mafodotin, sold under the brand name Blenrep, is a monoclonal antibody conjugated with a cytotoxic agent for the treatment of relapsed and refractory multiple myeloma. From Wikipedia
The MHRA authorizes Blenrep for relapsed or refractory multiple myeloma based on pivotal Phase 3 trial data, with reviews underway in 14 countries.
